A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients-Reference-Cited by-同舟云学术

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

Published:2021-03 Issue: Volume:33 Page:100787
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Ljungman Per^ORCID,Bermudez Arancha,Logan Aaron C.,Kharfan-Dabaja Mohamed A.,Chevallier Patrice,Martino Rodrigo,Wulf Gerald,Selleslag Dominik,Kakihana Kazuhiko,Langston Amelia,Lee Dong-Gun,Solano Carlos,Okamoto Shinichiro,Smith Larry R.,Boeckh Michael,Wingard John R.,Cywin Beth,Fredericks Christine,Lademacher Christopher,Wang Xuegong,Young James,Maertens Johan

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation;Kharfan-Dabaja;Expert Rev Vaccines,2015

2. How we treat cytomegalovirus in hematopoietic cell transplant recipients;Boeckh;Blood,2009

3. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study;Boeckh;Blood,1996

4. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome;Salzberger;Blood,1997

5. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant;Goodrich;Ann Intern Med,1993

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic vaccines for herpesviruses;Journal of Clinical Investigation;2024-05-01

2. Cytomegalovirus Infections in Hematopoietic Cell Transplant and Solid Organ Transplant Recipients;Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century;2024

3. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management. A report from the CMV International Symposium 2023;Transplant Infectious Disease;2023-11-09

4. Cytomegalovirus infection is associated with impaired myocardial flow reserve after heart transplantation;The Journal of Heart and Lung Transplantation;2023-10

5. Immunization of Solid Organ Transplant Candidates and Recipients;Infectious Disease Clinics of North America;2023-09